Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Sakaguchi, Takashi

doi:10.1093/jjco/hyf103

Cited by 7 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High-grade papillary urothelial carcinomas have a high risk of progression, with figures varying from 15% to 40%, and of association with invasive disease at the time of diagnosis (fig 1H, insert) 32 33…”

Section: Exophytic (Papillary) Urothelial Lesionsmentioning

confidence: 99%

Morphological diagnosis of urothelial neoplasms: Figure 1

et al. 2007

View full text Add to dashboard Cite

The morphological classification and diagnosis of bladder neoplasms is summarised, with specific focus on histological typing, grading and staging. Four diagnostic categories are described on the basis of the pattern of growth of the urothelial lesions and tumours (flat, exophytic or papillary, endophytic, and invasive). The WHO 2004 classification is currently used. However, the WHO 1973 classification is still considered by many urologists and oncologists as the international standard in patient management.

show abstract

Section: Exophytic (Papillary) Urothelial Lesionsmentioning

confidence: 99%

Morphological diagnosis of urothelial neoplasms: Figure 1

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The overall progression rate (to invasive carcinoma) ranges from 15% to 40% (Table 7). 41,42 These tumours, when non‐invasive (pTa), are all likely to require additional intravesicle therapy. Heterogeneity of grade is recognized in papillary lesions 43 and the consensus was that tumours should be graded on their worst part, although this needs further study.…”

mentioning

confidence: 99%

Morphological classification and definition of benign, preneoplastic and non‐invasive neoplastic lesions of the urinary bladder

et al. 2008

View full text Add to dashboard Cite

The morphological classification used in this essay has been based on the most recent World Health Organization (WHO) classification of tumours of the urinary system (i.e. 2004 WHO classification). It includes epithelial abnormalities and metaplasias as well as dysplasias and carcinomas in situ. The lesions are broadly subdivided into two major groups: benign, preneoplastic and non-invasive neoplastic lesions of the urothelium; and benign, preneoplastic and non-invasive neoplastic bladder lesions other than urothelial. Each of these lesions is defined with strict morphological criteria to provide more accurate information to urologists and oncologists in managing patients. There is still debate in the literature as to whether the 2004 WHO system should be the only one to be used and whether the 1973 WHO system should be abandoned.

show abstract

“…Most common presentation is with superficial disease. For superficial tumors diagnosis is made with resection of urinary bladder tumor and multiple biopsies with cystoscope and if needed mitomycin and BCG intravesically depending upon stage of NMIBC 1,2 . BCG is the gold standard treatment for intermediate and high-risk NMIBC since more than 50 years.…”

Section: Introductionmentioning

confidence: 99%

“…Evaluation and staging of urinary bladder tumor consist of the numbers, site and pattern of growth of urinary bladder tumors, depth of detrusor muscle invaded by tumor and peri-vesical fat invaded by tumor, and status of lymph node. 5% to 20% of superficial urinary bladder tumors are T1 and T1 is defined as lamina propria invasion without involving detrusor muscle 2,5 . Optimal treatment for T1G3 urinary bladder tumor is with complete resection of urinary bladder tumor through urethra.…”

Section: Introductionmentioning

confidence: 99%

Management of T1G3 Transitional Cell Carcinoma of Urinary Bladder with Intravesical Bacillus Calmette-Guerin (BCG): Our Experience

Ali,

Shaikh,

Ghani

et al. 2023

PJMHS

View full text Add to dashboard Cite

Aim: To determine efficacy of BCG in T1G3 urinary bladder tumors at department of urology Chandka Medical College Larkana. Patients and Methods: This is retrospective study, patient were selected from hospital record from July 2016 to June 2022. Around 80 included in our study group who were treated in our department for management of high grade non-muscle invasive bladder tumor. After following inclusion and exclusion criteria TURBT were performed and BCG was installed intravesically for induction and maintenance purpose. Patients were followed for 5 years and data was collected on study specific proforma. Results: 80 patients were included in our study with mean age 35year +5.5 SD. Transurethral resection of urinary bladder tumor was performed in all patients with bladder growth. Induction and maintenance instillation of bacillus Calmette-Guerin (BCG) therapy was given to all. The recurrence was noted in 5 patients (6.25%) and the progression was also seen in these 5 patients (6.25%). Disease-specific survival is 93.75% at the follow-up of 5 years. As prevalence of ca bladder is increasing day by day and bladder is sole organ for storing urine so nowadays strategies of treatment is bladder saving surgery. So patient will feel comfortable with natural bladder and on other hand it will minimize complication related to artificially generated urinary bladder. Conclusion: Maintenance BCG therapy for T1G3 bladder tumors is an effective treatment, with satisfactory results and bladder preservation. Keywords: Ca bladder, intravesival chemotherapy, BCG, T1G3 and management.

show abstract

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Abstract: The results suggest that superficial G3 bladder cancer could be treated with TUR initially, especially for papillary tumors.

Cited by 7 publications

References 19 publications

Morphological diagnosis of urothelial neoplasms: Figure 1

Morphological diagnosis of urothelial neoplasms: Figure 1

Morphological classification and definition of benign, preneoplastic and non‐invasive neoplastic lesions of the urinary bladder

Management of T1G3 Transitional Cell Carcinoma of Urinary Bladder with Intravesical Bacillus Calmette-Guerin (BCG): Our Experience

Contact Info

Product

Resources

About